Analyze Diet
Frontiers in veterinary science2024; 11; 1232650; doi: 10.3389/fvets.2024.1232650

Investigation of integrated time nanosecond pulse irreversible electroporation against spontaneous equine melanoma.

Abstract: Integrated time nanosecond pulse irreversible electroporation (INSPIRE) is a novel tumor ablation modality that employs high voltage, alternating polarity waveforms to induce cell death in a well-defined volume while sparing the underlying tissue. This study aimed to demonstrate the in vivo efficacy of INSPIRE against spontaneous melanoma in standing, awake horses. Unassigned: A custom applicator and a pulse generation system were utilized in a pilot study to treat horses presenting with spontaneous melanoma. INSPIRE treatments were administered to 32 tumors across 6 horses and an additional 13 tumors were followed to act as untreated controls. Tumors were tracked over a 43-85 day period following a single INSPIRE treatment. Pulse widths of 500ns and 2000ns with voltages between 1000 V and 2000 V were investigated to determine the effect of these variables on treatment outcomes. Unassigned: Treatments administered at the lowest voltage (1000 V) reduced tumor volumes by 11 to 15%. Higher voltage (2000 V) treatments reduced tumor volumes by 84 to 88% and eliminated 33% and 80% of tumors when 500 ns and 2000 ns pulses were administered, respectively. Unassigned: Promising results were achieved without the use of chemotherapeutics, the use of general anesthesia, or the need for surgical resection in regions which are challenging to keep sterile. This novel therapeutic approach has the potential to expand the role of pulsed electric fields in veterinary patients, especially when general anesthesia is contraindicated, and warrants future studies to demonstrate the efficacy of INSPIRE as a solid tumor treatment.
Publication Date: 2024-01-30 PubMed ID: 38352036PubMed Central: PMC10861690DOI: 10.3389/fvets.2024.1232650Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article discusses a novel technique called Integrated Time Nanosecond Pulse Irreversible Electroporation (INSPIRE) for effectively treating spontaneous melanoma in horses. The technique uses high voltage, alternating polarity waveforms which causes controlled cell death, while leaving the surrounding tissue unharmed.

Methodology and Test Subjects

  • The researchers used a unique applicator and a pulse generation system in a pilot study which involved horses diagnosed with spontaneous melanoma.
  • A total of 32 tumors across 6 horses were treated using the INSPIRE technique, while an additional 13 tumors were left untreated to serve as control.
  • The condition of the tumors was monitored over a period of 43 to 85 days after a single INSPIRE treatment.

Treatment Parameters and Effects

  • The researchers played around with pulse widths of 500ns and 2000ns and voltages between 1000 V and 2000 V to study their influence on the results of the treatment.
  • It was observed that treatments given at the lowest voltage of 1000 V reduced the size of the tumors by 11 to 15%.
  • Treatments given at a higher voltage of 2000 V, however, proved to be more effective, causing tumor volumes to reduce by 84 to 88%.
  • Specially, on administering 2000 V with 500 ns and 2000 ns pulses, 33% and 80% of the tumors respectively were completely eliminated.

Significance and Future Prospects of INSPIRE

  • INSPIRE has proved to be a promising method of tumor treatment without involving the use of chemotherapeutics, general anesthesia, or surgical resections in areas that are difficult to maintain sterile.
  • This technique can potentially broaden the role of pulsed electric fields in veterinary treatment especially in scenarios where general anesthesia can’t be used.
  • The success of INSPIRE as observed in the pilot study calls for further research into its efficacy as a solid tumor treatment method.

Cite This Article

APA
Fesmire CC, Peal B, Ruff J, Moyer E, McParland TJ, Derks K, O'Neil E, Emke C, Johnson B, Ghosh S, Petrella RA, DeWitt MR, Prange T, Fogle C, Sano MB. (2024). Investigation of integrated time nanosecond pulse irreversible electroporation against spontaneous equine melanoma. Front Vet Sci, 11, 1232650. https://doi.org/10.3389/fvets.2024.1232650

Publication

ISSN: 2297-1769
NlmUniqueID: 101666658
Country: Switzerland
Language: English
Volume: 11
Pages: 1232650

Researcher Affiliations

Fesmire, Chris C
  • Bioelectricity Lab, UNC/NCSU Joint Department of Biomedical Engineering, Raleigh, NC, United States.
Peal, Bridgette
  • Department of Clinical Sciences, NC State College of Veterinary Medicine, Raleigh, NC, United States.
Ruff, Jennifer
  • Department of Clinical Sciences, NC State College of Veterinary Medicine, Raleigh, NC, United States.
Moyer, Elizabeth
  • Department of Clinical Sciences, NC State College of Veterinary Medicine, Raleigh, NC, United States.
McParland, Thomas J
  • Department of Clinical Sciences, NC State College of Veterinary Medicine, Raleigh, NC, United States.
Derks, Kobi
  • Department of Clinical Sciences, NC State College of Veterinary Medicine, Raleigh, NC, United States.
O'Neil, Erin
  • Department of Clinical Sciences, NC State College of Veterinary Medicine, Raleigh, NC, United States.
Emke, Carrie
  • Clinical Studies Core, NC State College of Veterinary Medicine, Raleigh, NC, United States.
Johnson, Brianna
  • Clinical Studies Core, NC State College of Veterinary Medicine, Raleigh, NC, United States.
Ghosh, Shatorupa
  • Bioelectricity Lab, UNC/NCSU Joint Department of Biomedical Engineering, Raleigh, NC, United States.
Petrella, Ross A
  • Bioelectricity Lab, UNC/NCSU Joint Department of Biomedical Engineering, Raleigh, NC, United States.
DeWitt, Matthew R
  • Bioelectricity Lab, UNC/NCSU Joint Department of Biomedical Engineering, Raleigh, NC, United States.
Prange, Timo
  • Department of Clinical Sciences, NC State College of Veterinary Medicine, Raleigh, NC, United States.
Fogle, Callie
  • Department of Clinical Sciences, NC State College of Veterinary Medicine, Raleigh, NC, United States.
Sano, Michael B
  • Bioelectricity Lab, UNC/NCSU Joint Department of Biomedical Engineering, Raleigh, NC, United States.
  • Department of Molecular Biomedical Sciences, NC State College of Veterinary Medicine, Raleigh, NC, United States.

Grant Funding

  • R01 CA272550 / NCI NIH HHS
  • R01 CA276232 / NCI NIH HHS

Conflict of Interest Statement

CFe, RP, MD, and MS have intellectual property related to this manuscript and may receive royalties. MD and MS have ownership in Gradient Medical Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

This article includes 98 references
  1. Sullins KE. Melanocytic tumours in horses. Equine Vet Educ (2019) 32:624–30.
    doi: 10.1111/eve.13159google scholar: lookup
  2. van der Weyden L, Patton EE, Wood GA, Foote AK, Brenn T, Arends MJ. Cross-species models of human melanoma. J Pathol (2016) 238:152–65.
    doi: 10.1002/path.4632pmc: PMC4832391pubmed: 26354726google scholar: lookup
  3. MacKay RJ. Treatment options for melanoma of gray horses. Vet Clin Equine Pract (2019) 35:311–25.
    doi: 10.1016/j.cveq.2019.04.003pubmed: 31279435google scholar: lookup
  4. Rosengren Pielberg G, Golovko A, Sundström E, Curik I, Lennartsson J, Seltenhammer MH. A cis-acting regulatory mutation causes premature hair graying and susceptibility to melanoma in the horse. Nat Genet (2008) 40:1004–9.
    doi: 10.1038/ng.185pubmed: 18641652google scholar: lookup
  5. Curik I, Druml T, Seltenhammer M, Sundström E, Pielberg GR, Andersson L. Complex inheritance of melanoma and pigmentation of coat and skin in grey horses. PLoS Genet (2013) 9:e1003248.
  6. Rowe EL, Sullins KE. Excision as treatment of dermal melanomatosis in horses: 11 cases (1994–2000). J Am Vet Med Assoc (2004) 225:94–6.
    doi: 10.2460/javma.2004.225.94pubmed: 15239480google scholar: lookup
  7. Johnson PJ. Dermatologic tumors (excluding sarcoids). Vet Clin N Am Equine Pract (1998) 14:625–58.
    doi: 10.1016/S0749-0739(17)30190-6pubmed: 9891728google scholar: lookup
  8. Scott DW. Large animal dermatology. (1988).
  9. Sundberg J, Burnstein T, Page E, Kirkham W, Robinson F. Neoplasms of equidae. J Am Vet Med Assoc (1977) 170:150–2.
    pubmed: 576219
  10. Pimenta J, Prada J, Cotovio M. Equine melanocytic tumors: a narrative review. Animals (2023) 13:247.
    doi: 10.3390/ani13020247pmc: PMC9855132pubmed: 36670786google scholar: lookup
  11. Smith S, Goldschmidt M, McManus P. A comparative review of melanocytic neoplasms. Vet Pathol (2002) 39:651–78.
    doi: 10.1354/vp.39-6-651pubmed: 12450197google scholar: lookup
  12. Gorham S, Robl M. Melanoma in the gray horse: the darker side of equine aging. Vet Med (1986).
  13. Valentine BA. Equine melanocytic tumors: a retrospective study of 53 horses (1988 to 1991). J Vet Intern Med (1995) 9:291–7.
  14. Hewes CA. Review of the treatment of equine cutaneous neoplasia. AAEP Proceedings (2009).
  15. Groom L, Sullins K. Surgical excision of large melanocytic tumours in grey horses: 38 cases (2001–2013). Equi Vet Educ (2018) 30:438–43.
    doi: 10.1111/eve.12767google scholar: lookup
  16. Théon AP, Wilson WD, Magdesian KG, Pusterla N, Snyder JR, Galuppo LD. Long-term outcome associated with intratumoral chemotherapy with cisplatin for cutaneous tumors in equidae: 573 cases (1995–2004). J Am Vet Med Assoc (2007) 230:1506–13.
    doi: 10.2460/javma.230.10.1506pubmed: 17504043google scholar: lookup
  17. Hewes CA, Sullins KE. Use of cisplatin-containing biodegradable beads for treatment of cutaneous neoplasia in equidae: 59 cases (2000–2004). J Am Vet Med Assoc (2006) 229:1617–22.
    doi: 10.2460/javma.229.10.1617pubmed: 17107319google scholar: lookup
  18. Melanomas JK. Current therapy in equine medicine. Philadelphia: WB Saunders Co; (1997).
  19. Milner R, Salute M, Crawford C, Abbot J, Farese J. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine. Vet Immunol Immunopathol (2006) 114:273–84.
    doi: 10.1016/j.vetimm.2006.08.012pubmed: 17027091google scholar: lookup
  20. Trinchieri G. Proinflammatory and immunoregulatory functions of interleukin-12. Int Rev Immunol (1998) 16:365–96.
    doi: 10.3109/08830189809043002pubmed: 9505196google scholar: lookup
  21. Rubio-Martinez LM, Hendrickson DA. Complications in equine surgery. Hoboken, NJ: John Wiley & Sons; (2021).
  22. Cryosurgery RB. Cryosurgery. Annu Rev Biomed Eng (2000) 2:157–87.
  23. Steponkus PL. Role of the plasma membrane in freezing injury and cold acclimation. Annu Rev Plant Physiol (1984) 35:543–84.
  24. Hoffmann NE, Bischof JC. The cryobiology of cryosurgical injury. Urology (2002) 60:40–9.
    doi: 10.1016/S0090-4295(02)01683-7pubmed: 12206847google scholar: lookup
  25. Rabb J, Renaud M, Brandt P, Witt C. Effect of freezing and thawing on the microcirculation and capillary endothelium of the hamster cheek pouch. Cryobiology (1974) 11:508–18.
    doi: 10.1016/0011-2240(74)90120-5pubmed: 4452283google scholar: lookup
  26. Nagle WA, Soloff BL, Moss A, Jr, Henle KJ. Cultured Chinese hamster cells undergo apoptosis after exposure to cold but nonfreezing temperatures. Cryobiology (1990) 27:439–51.
    doi: 10.1016/0011-2240(90)90021-Upubmed: 2394128google scholar: lookup
  27. Roberts KP, Smith DJ, Ozturk H, Kazem A, Pazhayannur PV, Hulbert JC. Biochemical alterations and tissue viability in AT-1 prostate tumor tissue after in vitro cryodestruction. Cryo-Letters (1997) 18:241–50.
  28. Theon A. Cisplatin treatment for cutaneous tumors. Curr Ther Equine Med (1997) 4:372–7.
  29. Coughlin CM, Salhany KE, Wysocka M, Aruga E, Kurzawa H, Chang AE. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest (1998) 101:1441–52.
    doi: 10.1172/JCI1555pmc: PMC508700pubmed: 9502787google scholar: lookup
  30. Hashimoto W, Osaki T, Okamura H, Robbins PD, Kurimoto M, Nagata S. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand-and perforin-induced tumor apoptosis, respectively. J Immunol (1999) 163:583–9.
    doi: 10.4049/jimmunol.163.2.583pubmed: 10395644google scholar: lookup
  31. Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S-i, Okamura H. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-γ production. J Immunol (1998) 161:3400–7.
    doi: 10.4049/jimmunol.161.7.3400pubmed: 9759857google scholar: lookup
  32. Müller J-M, Feige K, Wunderlin P, Hödl A, Meli ML, Seltenhammer M. Double-blind placebo-controlled study with interleukin-18 and interleukin-12-encoding plasmid DNA shows antitumor effect in metastatic melanoma in gray horses. J Immunother (2011) 34:58–64.
    doi: 10.1097/CJI.0b013e3181fe1997pubmed: 21150713google scholar: lookup
  33. Mählmann K, Feige K, Juhls C, Endmann A, Schuberth H-J, Oswald D. Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma. BMC Vet Res (2015) 11:107.
    doi: 10.1186/s12917-015-0414-9pmc: PMC4429833pubmed: 25967290google scholar: lookup
  34. Heinzerling LM, Feige K, Rieder S, Akens MK, Dummer R, Stranzinger G. Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses. J Mol Med (2001) 78:692–02.
    doi: 10.1007/s001090000165pubmed: 11434722google scholar: lookup
  35. Greenberg CB, Javsicas LH, Clauson RM, Suckow MA, Kalinauskas AE, Lucroy MD. Field safety experience with an autologous cancer vaccine in 41 horses: a retrospective study (2019–2021). J Equine Vet (2022) 114:103948.
    doi: 10.1016/j.jevs.2022.103948pubmed: 35405291google scholar: lookup
  36. Brown EL, Ramiya VK, Wright CA, Jerald MM, Via AD, Kuppala VN. Treatment of metastatic equine melanoma with a plasmid DNA vaccine encoding streptococcus pyogenes EMM55 protein. J Equine Vet (2014) 34:704–8.
  37. Lembcke LM, Kania SA, Blackford JT, Trent DJ, Odoi A, Grosenbaugh DA. Development of immunologic assays to measure response in horses vaccinated with xenogeneic plasmid DNA encoding human tyrosinase. J Equine Vet (2012) 32:607–15.
  38. Phillips JC, Lembcke LM. Equine melanocytic tumors. Vet Clin Equine Pract (2013) 29:673–87.
    doi: 10.1016/j.cveq.2013.08.008pubmed: 24267683google scholar: lookup
  39. Ottnod J, Smedley R, Walshaw R, Hauptman J, Kiupel M, Obradovich J. A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma. Vet Comp Oncol (2013) 11:219–29.
    doi: 10.1111/vco.12057pubmed: 23909996google scholar: lookup
  40. Pellin MA. The use of Oncept melanoma vaccine in veterinary patients: a review of the literature. Vet Sci (2022) 9:597.
    doi: 10.3390/vetsci9110597pmc: PMC9693055pubmed: 36356074google scholar: lookup
  41. Tamzali Y, Borde L, Rols M, Golzio M, Lyazrhi F, Teissie J. Successful treatment of equine sarcoids with cisplatin electrochemotherapy: a retrospective study of 48 cases. Equine Vet J (2012) 44:214–20.
  42. Tozon N, Kramaric P, Kos Kadunc V, Sersa G, Cemazar M. Electrochemotherapy as a single treatment or adjuvant treatment to surgery of cutaneous sarcoid tumours in horses: a 31-case retrospective study. Vet Rec (2016) 179:627.
    doi: 10.1136/vr.103867pubmed: 27758950google scholar: lookup
  43. Byron CR, DeWitt MR, Latouche EL, Davalos RV, Robertson JL. Treatment of infiltrative superficial tumors in awake standing horses using novel high-frequency pulsed electrical fields. Front Vet Sci (2019) 6:265.
    doi: 10.3389/fvets.2019.00265pmc: PMC6705183pubmed: 31475163google scholar: lookup
  44. Geboers B, Scheffer HJ, Graybill PM, Ruarus AH, Nieuwenhuizen S, Puijk RS. High-voltage electrical pulses in oncology: irreversible electroporation, electrochemotherapy, gene electrotransfer, electrofusion, and electroimmunotherapy. Radiology (2020) 295:254–72.
    doi: 10.1148/radiol.2020192190pubmed: 32208094google scholar: lookup
  45. Gehl J, Skovsgaard T, Mir LM. Vascular reactions to in vivo electroporation: characterization and consequences for drug and gene delivery. Biochimica et Biophysica Acta (BBA)-General Subjects (2002) 1569:51–8.
    doi: 10.1016/S0304-4165(01)00233-1pubmed: 11853957google scholar: lookup
  46. Calvet CY, Famin D, André FM, Mir LM. Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells. Onco Targets Ther (2014) 3:e28131.
    doi: 10.4161/onci.28131pmc: PMC4111940pubmed: 25083316google scholar: lookup
  47. Ursic K, Kos S, Kamensek U, Cemazar M, Scancar J, Bucek S. Comparable effectiveness and immunomodulatory actions of oxaliplatin and cisplatin in electrochemotherapy of murine melanoma. Bioelectrochemistry (2018) 119:161–71.
  48. Bendix MB, Houston A, Forde PF, Brint E. Electrochemotherapy and immune interactions; a boost to the system?. Eur J Surg Oncol (2022) 48:1895–00.
    doi: 10.1016/j.ejso.2022.05.023pubmed: 35667946google scholar: lookup
  49. Spugnini EP, Baldi A. Electrochemotherapy in veterinary oncology: state-of-the-art and perspectives. Vet Clin Small Anim Pract (2019) 49:967–79.
    doi: 10.1016/j.cvsm.2019.04.006pubmed: 31176458google scholar: lookup
  50. Spugnini EP, Baldi A. Electrochemotherapy in veterinary oncology: from rescue to first line therapy. Electro Protoc (2014) 1121:247–56.
    doi: 10.1007/978-1-4614-9632-8_22pubmed: 24510829google scholar: lookup
  51. Davalos RV, Rubinsky B, Mir LM. Theoretical analysis of the thermal effects during in vivo tissue electroporation. Bioelectrochemistry (2003) 61:99–07.
  52. Kourounis G, Tabet PP, Moris D, Papalambros A, Felekouras E, Georgiades F. Irreversible electroporation (Nanoknife® treatment) in the field of hepatobiliary surgery: current status and future perspectives. J BU ON Off J Balkan Union Oncol (2017) 22:141–9.
    pubmed: 28365947
  53. Rossmeisl JH, Garcia PA, Pancotto TE, Robertson JL, Henao-Guerrero N, Neal RE. Safety and feasibility of the NanoKnife system for irreversible electroporation ablative treatment of canine spontaneous intracranial gliomas. J Neurosurg (2015) 123:1008–25.
    doi: 10.3171/2014.12.JNS141768pubmed: 26140483google scholar: lookup
  54. Neal RE, II, Rossmeisl JH, Jr, Garcia PA, Lanz OI, Henao-Guerrero N, Davalos RV. Successful treatment of a large soft tissue sarcoma with irreversible electroporation. J Clin Oncol (2011) 29:E372–e377.
    doi: 10.1200/JCO.2010.33.0902pubmed: 21321291google scholar: lookup
  55. Vroomen L, Petre EN, Cornelis FH, Solomon SB, Srimathveeravalli G. Irreversible electroporation and thermal ablation of tumors in the liver, lung, kidney and bone: what are the differences?. Diagn Interv Imaging (2017) 98:609–17.
    doi: 10.1016/j.diii.2017.07.007pubmed: 28869200google scholar: lookup
  56. Martin RC, 2nd, Kwon D, Chalikonda S, Sellers M, Kotz E, Scoggins C. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg (2015) 262:486–94.
    doi: 10.1097/SLA.0000000000001441pubmed: 26258317google scholar: lookup
  57. Fusco R, Di Bernardo E, D'Alessio V, Salati S, Cadossi M. Reduction of muscle contraction and pain in electroporation-based treatments: an overview. World J Clin Oncol (2021) 12:367–81.
    doi: 10.5306/wjco.v12.i5.367pmc: PMC8173331pubmed: 34131568google scholar: lookup
  58. Sano MB, Fan RE, Cheng K, Saenz Y, Sonn GA, Hwang GL. Reduction of muscle contractions during irreversible electroporation therapy using high frequency bursts of alternating polarity pulses: a laboratory investigation in an ex vivo swine model. J Vasc Interv Radiol (2017) 29:893–898.e4.
    doi: 10.1016/j.jvir.2017.12.019pubmed: 29628296google scholar: lookup
  59. Martin RC, Schwartz E, Adams J, Farah I, Derhake BM. Intra - operative anesthesia Management in Patients Undergoing Surgical Irreversible Electroporation of the pancreas, liver, kidney, and retroperitoneal tumors. Anesthesiol Pain Med (2015) 5:e22786.
    doi: 10.5812/aapm.22786pmc: PMC4493723pubmed: 26161319google scholar: lookup
  60. Deodhar A, Dickfeld T, Single GW, Hamilton WC, Jr, Thornton RH, Sofocleous CT. Irreversible electroporation near the heart: ventricular arrhythmias can be prevented with ECG synchronization. Am J Roentgenol (2011) 196:W330–5.
    doi: 10.2214/AJR.10.4490pmc: PMC4500941pubmed: 21343484google scholar: lookup
  61. Senior JM. Morbidity, mortality, and risk of general anesthesia in horses. Vet Clin Equine Pract (2013) 29:1–18.
    doi: 10.1016/j.cveq.2012.11.007pubmed: 23498043google scholar: lookup
  62. O’Donovan KA, Aarnes TK, Hubbell JA, Parker EM, Mollenkopf D, Lerche P. Risk of anesthesia-related complications in draft horses: a retrospective, single-center analysis. Vet Anaesth Analg (2023) 50:157–62.
    doi: 10.1016/j.vaa.2022.12.002pubmed: 36577561google scholar: lookup
  63. Johnston G, Eastment J, Taylor P, Wood J. Is isoflurane safer than halothane in equine anaesthesia? Results from a prospective multicentre randomised controlled trial. Equine Vet J (2004) 36:64–71.
    doi: 10.2746/0425164044864723pubmed: 14756374google scholar: lookup
  64. Johnston G, Eastment J, Wood J, Taylor P. The confidential enquiry into perioperative equine fatalities (CEPEF): mortality results of phases 1 and 2. Vet Anaesth Analg (2002) 29:159–70.
  65. Bidwell LA, Bramlage LR, Rood WA. Equine perioperative fatalities associated with general anaesthesia at a private practice–a retrospective case series. Vet Anaesth Analg (2007) 34:23–30.
  66. Young S, Taylor PM. Factors influencing the outcome of equine anaesthesia: a review of 1,314 cases. Equine Vet J (1993) 25:147–51.
  67. Arena CB, Sano MB, Rossmeisl JH, Caldwell JL, Garcia PA, Rylander MN. High-frequency irreversible electroporation (H-FIRE) for non-thermal ablation without muscle contraction. Biomed Eng Online (2011) 10:1–21.
    doi: 10.1186/1475-925X-10-102pmc: PMC3258292pubmed: 22104372google scholar: lookup
  68. Kaufman JD, Fesmire CC, Petrella RA, Fogle CA, Xing L, Gerber D. High-frequency irreversible electroporation using 5,000-V waveforms to create reproducible 2-and 4-cm ablation zones—a laboratory investigation using mechanically perfused liver. J Vasc Interv Radiol (2019) 31:162–168.e7.
    doi: 10.1016/j.jvir.2019.05.009pubmed: 31530492google scholar: lookup
  69. Sano MB, Arena CB, Bittleman KR, DeWitt MR, Cho HJ, Szot CS. Bursts of bipolar microsecond pulses inhibit tumor growth. Sci Rep (2015) 5:14999.
    doi: 10.1038/srep14999pmc: PMC4602310pubmed: 26459930google scholar: lookup
  70. Sano MB, Arena CB, DeWitt MR, Saur D, Davalos RV. In-vitro bipolar nano- and microsecond electro-pulse bursts for irreversible electroporation therapies. Bioelectrochemistry (2014) 100:69–79.
  71. Fesmire CC, Petrella RA, Kaufman JD, Topasna N, Sano MB. Irreversible electroporation is a thermally mediated ablation modality for pulses on the order of one microsecond. Bioelectrochemistry (2020) 135:107544.
  72. Sano MB, Fesmire CC, DeWitt MR, Xing L. Burst and continuous high frequency irreversible electroporation protocols evaluated in a 3D tumor model. Phys Med Biol (2018) 63:135022.
    doi: 10.1088/1361-6560/aacb62pubmed: 29978834google scholar: lookup
  73. Petrella RA, Fesmire CC, Kaufman JD, Topasna N, Sano MB. Algorithmically controlled electroporation: a technique for closed loop temperature regulated pulsed electric field Cancer ablation. IEEE Trans Biomed Eng (2020) 67:2176–86.
    doi: 10.1109/TBME.2019.2956537pubmed: 32673194google scholar: lookup
  74. Sano MB, Petrella RA, Kaufman JD, Fesmire CC, Xing L, Gerber D. Electro-thermal therapy: microsecond duration pulsed electric field tissue ablation with dynamic temperature control algorithms. Comput Biol Med (2020) 121:103807.
  75. Sano MB, Fesmire CC, Petrella RA. Electro-thermal therapy algorithms and active internal electrode cooling reduce thermal injury in high frequency pulsed electric field Cancer therapies. Ann Biomed Eng (2021) 49:191–02.
    doi: 10.1007/s10439-020-02524-xpubmed: 32415482google scholar: lookup
  76. Fesmire CC, Petrella RA, Fogle CA, Gerber DA, Xing L, Sano MB. Temperature dependence of high frequency irreversible electroporation evaluated in a 3D tumor model. Ann Biomed Eng (2020) 48:2233–46.
    doi: 10.1007/s10439-019-02423-wpubmed: 32409902google scholar: lookup
  77. Hasgall PA, Di Gennaro F, Baumgartner C, Neufeld E, Lloyd B, Gosselin MC. IT’IS database for thermal and electromagnetic parameters of biological tissues, version 4.0. IT’IS (2018).
  78. Arena CB, Garcia PA, Sano MB, Olson JD, Rogers-Cotrone T, Rossmeisl JH, Jr. Focal blood-brain-barrier disruption with high-frequency pulsed electric fields. Technology (2014) 2:206–13.
    doi: 10.1142/S2339547814500186google scholar: lookup
  79. Garcia PA, Neal RE, Ellis TL, Olson JD, Henao-Guerrero N. Intracranial nonthermal irreversible electroporation: in vivo analysis. J Membr Biol (2010) 236:127–36.
    doi: 10.1007/s00232-010-9284-zpubmed: 20668843google scholar: lookup
  80. Yi Z, Gao Y, Yu F, Zhu Y, Liu H, Li J. Interventions for treatment of cutaneous melanoma in horses: a structured literature review. Vet Res Commun (2023) 47:347–60.
    doi: 10.1007/s11259-022-10023-8pubmed: 36329228google scholar: lookup
  81. Robinson EP, Natalini CC. Epidural anesthesia and analgesia in horses. Vet Clin Equine Pract (2002) 18:61–82, vi.
    pubmed: 12064183
  82. Spugnini EP, D'Alterio GL, Dotsinsky I, Mudrov T, Dragonetti E, Murace R. Electrochemotherapy for the treatment of multiple melanomas in a horse. J Equine Vet (2011) 31:430–3.
  83. Rogers WR, Merritt JH, Comeaux JA, Jr, Kuhnel CT, Moreland DF, Teltschik DG. Strength-duration curve for an electrically excitable tissue extended down to near 1 nanosecond. IEEE Trans Plasma Sci (2004) 32:1587–99.
    doi: 10.1109/TPS.2004.831758google scholar: lookup
  84. Garcia PA, Neal RE, Sano MB, Robertson JL, Davalos RV. An experimental investigation of temperature changes during electroporation. 2011 XXXth URSI General Assembly and Scientific Symposium (2011).
  85. Garcia PA, Arena CB, Neal RE, Goldberg SN, Ben-David E, Davalos RV. Adapting the Cassini Curve to Approximate In Vivo Irreversible Electroporation Ablations in Porcine Liver. ASME 2013 Summer Bioengineering Conference (2013).
  86. Fesmire CC, Williamson RH, Petrella RA, Kaufman JD, Topasna N, Sano MB. Integrated time nanosecond pulse irreversible electroporation (INSPIRE): assessment of dose, temperature, and voltage on experimental and clinical treatment outcomes. IEEE Trans Biomed Eng (2023):1–10.
    doi: 10.1109/TBME.2023.3340718pmc: PMC11035095pubmed: 38145519google scholar: lookup
  87. Sano MB, DeWitt MR, Teeter SD, Xing L. Optimization of a single insertion electrode array for the creation of clinically relevant ablations using high-frequency irreversible electroporation. Comput Biol Med (2018) 95:107–17.
  88. Sano MB, Fan RE, Hwang GL, Sonn GA, Xing L. Production of spherical ablations using nonthermal irreversible electroporation: a laboratory investigation using a Single electrode and grounding pad. J Vasc Intervent Radiol JVIR (2016) 27:1432–1440.e3.
    doi: 10.1016/j.jvir.2016.05.032pubmed: 27478129google scholar: lookup
  89. Tremble LF, O'Brien MA, Soden DM, Forde PF. Electrochemotherapy with cisplatin increases survival and induces immunogenic responses in murine models of lung cancer and colorectal cancer. Cancer Lett (2019) 442:475–82.
    doi: 10.1016/j.canlet.2018.11.015pubmed: 30472183google scholar: lookup
  90. He C, Huang X, Zhang Y, Lin X, Li S. T-cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer. Clin Transl Med (2020) 10:e39.
    doi: 10.1002/ctm2.39pmc: PMC7403705pubmed: 32508058google scholar: lookup
  91. Dai Z, Wang Z, Lei K, Liao J, Peng Z, Lin M. Irreversible electroporation induces CD8+ T cell immune response against post-ablation hepatocellular carcinoma growth. Cancer Lett (2021) 503:1–10.
    doi: 10.1016/j.canlet.2021.01.001pubmed: 33444692google scholar: lookup
  92. Justesen TF, Orhan A, Raskov H, Nolsoe C, Gögenur I. Electroporation and immunotherapy—unleashing the abscopal effect. Cancers (2022) 14:2876.
    doi: 10.3390/cancers14122876pmc: PMC9221311pubmed: 35740542google scholar: lookup
  93. Brock RM, Beitel-White N, Davalos RV, Allen IC. Starting a Fire without flame: the induction of cell death and inflammation in electroporation-based tumor ablation strategies. Front Oncol (2020) 10:1235.
    doi: 10.3389/fonc.2020.01235pmc: PMC7399335pubmed: 32850371google scholar: lookup
  94. Edelblute CM, Hornef J, Burcus NI, Norman T, Beebe SJ, Schoenbach K. Controllable moderate heating enhances the therapeutic efficacy of irreversible electroporation for pancreatic Cancer. Sci Rep (2017) 7:11767.
    doi: 10.1038/s41598-017-12227-4pmc: PMC5603521pubmed: 28924200google scholar: lookup
  95. Zhao J, Wen X, Tian L, Li T, Xu C, Wen X. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer. Nat Commun (2019) 10:899.
    doi: 10.1038/s41467-019-08782-1pmc: PMC6385305pubmed: 30796212google scholar: lookup
  96. Ganbaatar O, Konnai S, Okagawa T, Nojima Y, Maekawa N, Minato E. PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade. PLoS One (2020) 15:e0234218.
  97. Porcellato I, Mecocci S, Brachelente C, Cappelli K, Armando F, Tognoloni A. PD-L1/PD-1 and CTLA-4 expression in equine penile squamous cell carcinomas. Animals (2021) 11:2121.
    doi: 10.3390/ani11072121pmc: PMC8300259pubmed: 34359249google scholar: lookup
  98. Benvegnen J, De Breuyn B, Gerber V, Rottenberg S, Koch C. Immunohistochemical analysis of programmed death-ligand 1 expression in equine sarcoids. J Equine Vet (2021) 97:103338.
    doi: 10.1016/j.jevs.2020.103338pubmed: 33478763google scholar: lookup